Shots:

• Halozyme to receive $30M upfront- $160M milestones- $10M per future target nominations and royalties on sales of products. Argenx to get an exclusive license for Halozyme’s ENHANZE technology targeting ARGX-113 and additional two human neonatal Fc receptors (FcRn)  
• The focus of this ninth agreement b/w the companies- is to develop and commercialize neonatal Fc receptors with SC delivery- utilizing Halozyme’s ENHANZE technology for severe autoimmune disease
• Halozyme’s ENHANZE is a drug delivery technology based on recombinant human hyaluronidase enzyme (rHuPH20) used for reducing the need for multiple injections- health care practitioner time and time for drug administration

   Ref: Argenx | Image:The Pharmaletter